Collaborative arrangement, consideration received as preferred shares, value.

No definition available.

Name:	kdny_CollaborativeArrangementConsiderationReceivedAsPreferredSharesValue
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangement,consideration received as warrants, value.

+ References

No definition available.

+ Details

Name:	kdny_CollaborativeArrangementConsiderationReceivedAsWarrantsValue
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative arrangement, milestone payment

+ References

No definition available.

+ Details

Name:	kdny_CollaborativeArrangementMilestonesPayment
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Contingent development, regulatory and commercial milestone payments.

+ References

No definition available.

+ Details

Name:	kdny_ContingentDevelopmentRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Progress-dependent cash milestone payments receivable.

+ References

No definition available.

+ Details

Name:	kdny_ProgressDependentCashMilestonePaymentsReceivable
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Progress-dependent milestone payments and royalties received.

+ References

No definition available.

+ Details

Name:	kdny_ProgressDependentMilestonePaymentsAndRoyaltiesReceived
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue recognition milestone method eligible revenue for each product or product candidate.

+ References

No definition available.

+ Details

Name:	kdny_RevenueRecognitionMilestoneMethodEligibleRevenueForEachProductOrProductCandidate
Namespace Prefix:	kdny_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585

+ Details

Name:	us-gaap_ProceedsFromIssuanceOfCommonStock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares authorized for issuance under share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_TypeOfArrangementAxis=kdny_ChinaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=kdny_SanRenoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=kdny_AbbVieAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=kdny_MerckMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=kdny_ProductCandidateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=kdny_LillyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaboration and License Agreements - Additional Information (Details) - USD ($)		1 Months Ended	12 Months Ended
	Dec. 16, 2019	Nov. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
China License Agreement \| SanReno
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Consideration received as preferred shares		$ 40,000,000.0
Consideration received as warrants		1,200,000
Revenue recognized			$ 41,200,000
Progress-dependent milestone payments and royalties received			0
China License Agreement \| SanReno \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Progress-dependent milestone receivable		$ 25,000,000.0
AbbVie Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Common stock shares issued	2,000,000.0
Proceeds from issuance of common stock	$ 6,700,000
Milestone payment			0	$ 0
AbbVie Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent development, regulatory and commercial milestone payments	$ 135,000,000.0
Merck
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized			10,000,000.0
Merck \| Maximum \| Product Candidate
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates			287,000,000.0
Merck \| Maximum \| Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates			135,000,000.0
Lilly Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized			400,000	$ 800,000
Lilly Agreement \| Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates			$ 464,900,000